GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (NYSE:NVO) » Definitions » Cyclically Adjusted Revenue per Share

NVO (Novo Nordisk AS) Cyclically Adjusted Revenue per Share : $5.53 (As of Mar. 2025)


View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk AS Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Novo Nordisk AS's adjusted revenue per share for the three months ended in Mar. 2025 was $2.545. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $5.53 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Novo Nordisk AS's average Cyclically Adjusted Revenue Growth Rate was 16.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 16.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Novo Nordisk AS was 16.10% per year. The lowest was 6.30% per year. And the median was 11.80% per year.

As of today (2025-07-05), Novo Nordisk AS's current stock price is $69.17. Novo Nordisk AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $5.53. Novo Nordisk AS's Cyclically Adjusted PS Ratio of today is 12.51.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novo Nordisk AS was 31.25. The lowest was 8.17. And the median was 12.10.


Novo Nordisk AS Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Novo Nordisk AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Cyclically Adjusted Revenue per Share Chart

Novo Nordisk AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.35 3.49 3.93 4.55 4.93

Novo Nordisk AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.69 4.72 5.21 4.93 5.53

Competitive Comparison of Novo Nordisk AS's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Cyclically Adjusted PS Ratio falls into.


;
;

Novo Nordisk AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novo Nordisk AS's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=2.545/120.2000*120.2000
=2.545

Current CPI (Mar. 2025) = 120.2000.

Novo Nordisk AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.788 100.300 0.944
201509 0.784 100.200 0.940
201512 0.827 99.800 0.996
201603 0.797 100.200 0.956
201606 0.816 100.600 0.975
201609 0.819 100.200 0.982
201612 0.833 100.300 0.998
201703 0.818 101.200 0.972
201706 0.881 101.200 1.046
201709 0.863 101.800 1.019
201712 0.904 101.300 1.073
201803 0.913 101.700 1.079
201806 0.884 102.300 1.039
201809 0.897 102.400 1.053
201812 0.942 102.100 1.109
201903 0.927 102.900 1.083
201906 0.953 102.900 1.113
201909 0.941 102.900 1.099
201912 1.020 102.900 1.191
202003 1.063 103.300 1.237
202006 0.966 103.200 1.125
202009 1.049 103.500 1.218
202012 1.130 103.400 1.314
202103 1.168 104.300 1.346
202106 1.160 105.000 1.328
202109 1.227 105.800 1.394
202112 1.270 106.600 1.432
202203 1.363 109.900 1.491
202206 1.288 113.600 1.363
202209 1.336 116.400 1.380
202212 1.514 115.900 1.570
202303 1.701 117.300 1.743
202306 1.755 116.400 1.812
202309 1.872 117.400 1.917
202312 2.154 116.700 2.219
202403 2.131 118.400 2.163
202406 2.198 118.500 2.230
202409 2.380 118.900 2.406
202412 2.702 118.900 2.732
202503 2.545 120.200 2.545

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Novo Nordisk AS  (NYSE:NVO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novo Nordisk AS's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=69.17/5.53
=12.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novo Nordisk AS was 31.25. The lowest was 8.17. And the median was 12.10.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Novo Nordisk AS Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Industry
Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.